-
EP0866719
European procedure
Extract from the Register of European Patents
EP About this file: EP0866719
| EP0866719 - METHOD FOR TREATING RETINAL GANGLION CELL INJURY USING GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR (GDNF) PROTEIN PRODUCT [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 27.04.2001 Database last updated on 03.09.2024 | Most recent event Tooltip | 27.04.2001 | No opposition filed within time limit | published on 13.06.2001 [2001/24] | Applicant(s) | For all designated states Amgen Inc. One Amgen Center Drive Thousand Oaks California 91320-1799 / US | [N/P] |
| Former [2000/51] | For all designated states Amgen Inc. One Amgen Center Drive Thousand Oaks, CA 91320-1789 / US | ||
| Former [1998/40] | For all designated states AMGEN INC. Amgen Center, One Amgen Center Drive Thousand Oaks, CA 91320-1789 / US | Inventor(s) | 01 /
YANG, Qiao 1848 Marview Drive Thousand Oaks, CA 91362 / US | 02 /
LOUIS, Jean-Claude Marcel 3022 Windrift Court Thousand Oaks, CA 91320 / US | [1998/40] | Representative(s) | Vossius, Volker, et al ZSP Patentanwälte PartG mbB Radlkoferstrasse 2 81373 München / DE | [N/P] |
| Former [1998/40] | Vossius, Volker, Dr., et al Dr. Volker Vossius, Patentanwaltskanzlei - Rechtsanwaltskanzlei, Holbeinstrasse 5 81679 München / DE | Application number, filing date | 96942805.1 | 22.11.1996 | [1998/40] | WO1996US18851 | Priority number, date | US19950564458 | 29.11.1995 Original published format: US 564458 | [1998/40] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO9719695 | Date: | 05.06.1997 | Language: | EN | [1997/24] | Type: | A1 Application with search report | No.: | EP0866719 | Date: | 30.09.1998 | Language: | EN | The application published by WIPO in one of the EPO official languages on 05.06.1997 takes the place of the publication of the European patent application. | [1998/40] | Type: | B1 Patent specification | No.: | EP0866719 | Date: | 28.06.2000 | Language: | EN | [2000/26] | Search report(s) | International search report - published on: | EP | 05.06.1997 | Classification | IPC: | A61K38/18 | [1998/40] | CPC: |
A61K38/185 (EP,US);
A61K38/18 (KR);
A61P25/00 (EP);
A61P25/02 (EP);
A61P27/00 (EP);
A61P27/06 (EP)
| Designated contracting states | AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE [1998/40] | Extension states | AL | 19.05.1998 | LT | 19.05.1998 | LV | 19.05.1998 | RO | 19.05.1998 | SI | 19.05.1998 | Title | German: | VERFAHREN ZUR BEHANDLUNG VON VERLETZUNGEN RETINALER GANGLIONE MIT NEUROTROPHISCHEM FAKTOR AUS DER GLIALZELLINIE (GDNF) | [1999/40] | English: | METHOD FOR TREATING RETINAL GANGLION CELL INJURY USING GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR (GDNF) PROTEIN PRODUCT | [1998/40] | French: | METHODE POUR TRAITER LES BLESSURES DES CELLULES GANGLIONNAIRES DE LA RETINE EN UTILISANT UN PRODUIT PROTEIQUE DE TYPE FACTEUR NEUROTROPHIQUE DERIVE DE LIGNEE CELLULAIRE GLIALE (GDNF) | [2000/04] |
| Former [1998/40] | VERFAHREN ZUR BEHANDLUNG RETINALES GANGLION MIT GLIAL ZELLINIE-ABGELEITETE NEUROTROPHISCHER FAKTOR (GDNF) PROTEINPRODUKT | ||
| Former [1998/40] | METHODE POUR TRAITER LES BLESSURES DES CELLULES GANGLIONNAIRES DE LA RETINE EN UTILISANT UN AGENT PROTEIQUE NEUROTROPHIQUE OBTENU DE LIGNEES DE CELLULES GLIALES | Entry into regional phase | 19.05.1998 | National basic fee paid | 19.05.1998 | Designation fee(s) paid | 19.05.1998 | Examination fee paid | Examination procedure | 16.05.1997 | Request for preliminary examination filed International Preliminary Examining Authority: US | 19.05.1998 | Examination requested [1998/40] | 19.05.1998 | Request for accelerated examination filed | 01.02.1999 | Despatch of a communication from the examining division (Time limit: M04) | 01.02.1999 | Decision about request for accelerated examination - accepted: Yes | 02.06.1999 | Reply to a communication from the examining division | 27.12.1999 | Despatch of communication of intention to grant (Approval: No) | 18.04.2000 | Despatch of communication of intention to grant (Approval: later approval) | 18.04.2000 | Fee for grant paid | 18.04.2000 | Fee for publishing/printing paid | 03.05.2000 | Communication of intention to grant the patent | Opposition(s) | 29.03.2001 | No opposition filed within time limit [2001/24] | Fees paid | Renewal fee | 10.11.1998 | Renewal fee patent year 03 | 12.11.1999 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [DA]EP0401384 (KIRIN AMGEN INC [US]); | [XD]WO9306116 (SYNTEX INC [US]); | [X]WO9315722 (SYNTEX INC [US]); | [X]WO9517203 (UNIV NEW JERSEY MED [US]); | [XP]WO9614861 (AMGEN BOULDER INC [US], et al) |